Mirum Pharmaceuticals (NASDAQ:MIRM) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen lowered shares of Mirum Pharmaceuticals (NASDAQ:MIRM) from a strong-buy rating to a hold rating in a report published on Saturday morning.

A number of other equities research analysts have also recently commented on the stock. Citizens Jmp dropped their price objective on shares of Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating on the stock in a research note on Thursday. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $110.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Morgan Stanley boosted their price objective on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Finally, Leerink Partners dropped their price target on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $114.92.

Mirum Pharmaceuticals Trading Up 0.1%

NASDAQ MIRM opened at $92.29 on Friday. The stock has a market cap of $5.57 billion, a P/E ratio of -192.27 and a beta of 0.49. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals has a 12-month low of $36.88 and a 12-month high of $109.28. The company has a fifty day simple moving average of $93.40 and a two-hundred day simple moving average of $79.18.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.13). The business had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.98% and a negative net margin of 4.48%.Mirum Pharmaceuticals’s quarterly revenue was up 49.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.00 EPS. On average, analysts forecast that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Insider Activity at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 968 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $99,994.40. Following the completion of the sale, the senior vice president directly owned 4,503 shares in the company, valued at $465,159.90. This represents a 17.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher Peetz sold 9,108 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $940,856.40. Following the transaction, the chief executive officer owned 160,294 shares in the company, valued at $16,558,370.20. The trade was a 5.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 45,136 shares of company stock worth $4,352,029 over the last 90 days. Corporate insiders own 14.36% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Cullen Frost Bankers Inc. purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth $30,000. MCF Advisors LLC boosted its holdings in Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares during the last quarter. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at approximately $32,000. CIBC Private Wealth Group LLC purchased a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at approximately $32,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $33,000.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and strong product growth — Mirum reported ~50% year-over-year revenue growth driven by Livmarli and other drug sales, topping estimates and providing fundamental support for the stock. Mirum’s Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
• Positive Sentiment: Analyst upgrades/target raises — Stifel raised its price target to $125 (buy) and TD Cowen raised its target to $117 (buy), signaling continued analyst confidence and suggesting meaningful upside from current levels. Analyst Coverage (Benzinga)
• Neutral Sentiment: Analyst consensus roundup — several coverage notes were published (13-analyst roundup) that summarize mixed but generally constructive views; useful for gauging street positioning. 13 Analysts Have This To Say About Mirum Pharmaceuticals
• Neutral Sentiment: Other analyst moves — RBC and Citizens JPM trimmed targets modestly but kept outperform/market outperform ratings, indicating conviction despite small PT adjustments. RBC Commentary (Street Insider)
• Neutral Sentiment: Earnings call and transcripts available — management commentary from the Q4 call provides more detail on commercialization cadence and upcoming catalysts; worth reviewing for guidance tone and commercialization cadence. Q4 2025 Earnings Call Transcript (Fool)
• Negative Sentiment: EPS miss — Mirum reported a GAAP loss of ($0.11) vs. consensus of $0.02, a notable EPS miss that can weigh on sentiment despite the revenue beat. Mirum Reports Q4 Loss, Tops Revenue Estimates (Zacks)
• Negative Sentiment: Guidance mixed — management set FY2026 revenue guidance of $630–$650M vs. a consensus near $646M, leaving limited upside to Street expectations and creating potential downside if execution slips. Press Release / Guidance (Company PDF)
• Negative Sentiment: Short-term pullback coverage — commentary and retail pieces explaining intra-day/short-term weakness (e.g., articles on why MIRM was down) may amplify volatility even as fundamentals improve. Why MIRM Stock Is Down 13.46% (AAII)

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.